1. Scrip
  2. >>Business

Novartis Benefits From Biotech Lessons Taught By Development Head Aradhye

 
• By Kevin Grogan

The Swiss major’s chief medical officer tells Scrip about how “an R&D/commercial continuum” is helping to speed up innovation across the group.

Shreeram Aradhye (Novartis)

Novartis has been heralding its slimmed-down, more-focused pipeline to analysts for which much of the credit goes to Shreeram Aradhye, who after a spell in US biotech returned to his roots with the Swiss firm a couple of years ago to become president, development and chief medical officer.

A transplant nephrologist by training, Aradhye joined Novartis in 1999 and spent 20 years in the company in high-profile posts in medical affairs and development before heading to Boston and the world of biotech in 2019, including leading the development of multiple clinical stage RNAi assets at Dicerna Pharmaceuticals

More from Business

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

 
• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.

Regeneron Sees 23andMe Buy As Complement To Genetics Platform

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

How Much Does Biopharma Contribute To The US Economy?

 
• By Jessica Merrill

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

More from Therapy Areas

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.